Karan Johar: 'I did not take Ozempic for weight loss'
Filmmaker Karan Johar shuts down Ozempic rumours, opens up about his weight loss journey, thyroid issues, and his mother's blunt honesty. Read his full story.
Filmmaker Karan Johar shuts down Ozempic rumours, opens up about his weight loss journey, thyroid issues, and his mother's blunt honesty. Read his full story.
Filmmaker Karan Johar opens up about his weight loss journey, dismissing Ozempic rumours. He recalls his mother's comments, fainting in college, and discovering gluten intolerance.
A new BMJ study reveals alarming weight regain after stopping drugs like Ozempic. Experts warn against treating them as short-term trends. Learn the facts and risks.
A new BMJ study reveals that discontinuing weight-loss drugs like Ozempic and Mounjaro leads to regaining all lost weight within 1.5 years. Experts advise on long-term management strategies.
In a NYT interview, Donald Trump revealed he hasn't used GLP-1 drugs like Ozempic, sparking debate on obesity, healthcare costs, and his administration's drug price policies. Read the full story.
Natco Pharma files suit in Delhi High Court seeking revocation of Novo Nordisk's patent on diabetes drug semaglutide. Court issues notice, hearing set for Feb 5. Indian pharma race for generic Ozempic heats up.
Explore the high-stakes legal battles between Indian generic manufacturers and global pharma giants. Understand the impact on drug prices, accessibility, and the evolving IP landscape in India.
Oatzempic, a viral oat-based drink, is being hailed as a natural alternative to weight loss injections. Discover its recipe, benefits, and the expert warnings you need to know before trying it.
The 'Oatzempic' drink is trending on TikTok for weight loss. Experts reveal if this oat-based concoction can truly mimic the effects of the prescription drug Ozempic or if it's just another fad.
A citizen-funded study finds generic medicines, including Jan Aushadhi, match quality of expensive brands. Experts urge trust in affordable options for better treatment adherence. #Healthcare #India
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
The patent expiry of Novo Nordisk's blockbuster drug semaglutide (Ozempic, Wegovy) opens a massive Rs 50,000+ crore market for Indian generic drugmakers, a new report reveals.
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
From preventive screenings to affordable generics, 2025 reshaped India's health priorities. Discover the key trends that made wellness a daily habit and what it means for 2026.
New research reveals bariatric surgery delivers five times more weight loss than GLP-1 drugs like Ozempic over two years. Discover the real-world data and what it means for obesity treatment.
Explore how 2025's weight-loss drug boom in India shifted focus from fitness to thinness, raising concerns about medicalisation, side effects, and societal pressure. Read the full analysis.
As GLP-1 drugs like Ozempic launched in India, experts warn they are not a magic fix. Sustainable metabolic health requires diet, exercise, and stress management. Learn why.
Explore the social and economic impact of GLP-1 drugs like Ozempic & Mounjaro in India. A ₹1,000 crore market is poised for massive growth. Share your thoughts.
New research reveals GLP-1 weight-loss drugs like Ozempic significantly cut grocery and restaurant spending. Discover the impact on food habits in India and globally.
Zota Health Care secures ₹350 crore from investors via QIP to fund expansion. MS Dhoni & Suniel Shetty join as brand ambassadors. Aim to open 5000+ generic pharmacy stores by 2029.
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
Women share harrowing experiences of stopping anti-obesity drugs like Wegovy. Experts warn 60-80% weight returns without a plan. Learn about the side effects and new drugs in India.
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
Rapid weight loss from GLP-1 drugs like Ozempic is causing 'Ozempic face'—facial thinning & sagging. Learn about prevention, treatments, and the 50% rise in cosmetic procedures. #Beauty #Skincare
The Indian government is considering data exclusivity for pharma, a move that could delay cheap generic drugs, impact India's global edge, and affect medicine access. Read the full analysis.
The Indian government mandates a 500-meter distance between Jan Aushadhi Kendras in major cities to protect store viability and ensure access to affordable generic medicines. Learn about the new policy's impact.
Bangladesh's pharma firms have a 2-year head start over Indian giants like Dr Reddy's in exporting generic semaglutide. Delhi HC allows exports, but domestic sales wait until 2026. Explore the competitive landscape.
Actor Ram Kapoor opens up about his 55kg weight loss journey, battling type-2 diabetes, and his mindset shift. Discover his inspiring health transformation story.